HDACi and Sodium Butyrate for cancer STEM cells

Dr. Weeks’ Comment:   even Dr. Wicha recommends to patients with cancer: “see if you are eligible for a clinical trial” as regards treatment for cancer STEM cells.   What clinical trials are available?


“Clinical trials of several HDACi’s are currently underway, as monotherapies or in combination with other anticancer drugs and radiation. A total of 140 studies for cancer are found in website of U.S. NIH (www.clinicaltrials.gov). SAHA and depsipeptide have been approved by the FDA for cancer therapy (26, 27). HDACi’s emerge as promising drugs for targeting of cancer stem-like cells in clinical setting. “


SO….  What is a “HDACi?”


The regulation of histone acetylation is a major mechan- ism controlling cellular differentiation and the biological phenotype of cancer cells (17). Histone deacetylases (HDAC) and histone acetyl transferases are enzymes that ensure the homeostatic levels of histone acetylation. Deregulated HDAC activity has been found in certain human cancers (18-22). Several studies have shown the antiproliferative or the proapoptotic effects of HDAC inhibitors (HDACi) on endometrial cancer cells (23-25). Thus, HDACs are important therapeutic targets for cancer and several HDACi’s are in various stages of clinical development (26, 27).  


Where can you get a HDCAi?

Go to your health food store and buy  some Sodium Butyrate.


Sodium Butyrate Inhibits the Self-Renewal Capacity of Endometrial Tumor Side-Population Cells by Inducing a DNA Damage Response

Mol Cancer Ther 2011;10:1430-1439. Published OnlineFirst June 1, 2011.

  1. Authors’ Affiliations:1Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, Hongo 2-1-1, Bunkyo-ku, Tokyo; and 2Department of Obstetrics and Gynecology, School of Medicine, Kyushu University Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan



Leave a Comment

Your email address will not be published. Required fields are marked *